Analysts' Actions: BAC BIIB GS JPM MDT

TheStreet.com

NEW YORK (TheStreet) -- CHANGE IN RATINGS:

Align Technology ALGN was upgraded at Morgan Stanley from underweight to equal weight. Company should see better consumer trends and easing competition, Morgan Stanley said.

Allot Communications ALLT was downgraded at Oppenheimer to perform from outperform. Checks point to slowdown, Oppenheimer said.

Bank of America BAC was upgraded at JMP Securities from underperform to market perform. Estimates were also boosted, given higher expected industry sales growth, JMP said.

CR Bard BCR was downgraded at Morgan Stanley from equal weight to underweight. $91 price target. Company has a premium valuation, but is growing slower than its peers, Morgan Stanley said.

Biogen Idec BIIB was downgraded at Piper Jaffray from overweight to neutral. Valuation call, based on a $168 price target, Piper Jaffray said.

Citigroup C was upgraded at JMP Securities from underperform to market perform. Company is leveraged to continued economic growth, JMP said.

Citigroup was upgraded at Sterne Agee to buy from neutral. $50 price target. New CEO is a positive and the company remains the cheapest stock in the sector, Sterne Agee said.

Clear Channel Outdoor Holdings CCO was downgraded at Wedbush to underperform from neutral. $6 price target. Weak 4Q checks, Wedbush said.

DR Horton DHI was upgraded at Stifel Nicolaus from sell to hold. Valuation call, as the sector has sustainable growth tailwinds, Stifel Nicolaus said.

Synageva GEVA was downgraded at Piper Jaffray from overweight to neutral. $57 price target. Company lacks near-term catalysts, Piper Jaffray said.

Goldman Sachs GS was upgraded at JMP Securities from underperform to market perform. Earnings should improve in the coming quarters, JMP Securities said.

Health Net was upgraded at Deutsche Bank from sell to hold. Valuation call, Deutsche Bank said.

JPMorgan Chase was upgraded at JMP Securities from underperform to market perform. Industry should see higher sales in key areas, JMP said.

Kronos Worldwide KRO was downgraded at Oppenheimer to perform from outperform. Comps will remain negative in the first half, Oppenheimer said.

Medtronic MDT was upgraded at Mizuho from neutral to buy. $49 price target. Spine business should grow through new products and insurance expansion, Mizuho said.

Morgan Stanley MS was upgraded at JMP Securities from underperform to market perform. Near-term policy risk has been lifted in the U.S. and Europe, JMP said.

Myriad Genetics MYGN was downgraded at JP Morgan to underweight. Supreme Court ruling on ACLU case may hang over the stock, JP Morgan said.

Priceline.com PCLN was upgraded at Bank of America/Merrill Lynch from neutral to buy. $770 price target. Company has better earnings upside potential than Expedia, BofA/Merrill said.

Ryland RYL was downgraded at Topeka from buy to hold. Valuation call, based on a $65 price target, Topeka said.

Toll Brothers TOL upgraded at Stifel Nicolaus to hold from sell. Company has lost its premium valuation, and the housing market should remain strong, Stifel Nicolaus said.

UnitedHealth UNH was downgraded at Deutsche Bank from buy to hold. $61 price target. Price competition appears to be increasing, Deutsche said.

Waters WAT was downgraded at Leerink Swann from outperform to market perform. Company may struggle to exceed consensus earnings expectations, Leerink Swann said.

Waters was downgraded at JP Morgan from overweight to neutral. Company is operating near peak margins and may face increased competition, JP Morgan said.

Wellpoint WLP was downgraded at Deutsche Bank from buy to hold. $68 price target. Industry price increases are slowing, Deutsche Bank said.

Stock Comments / EPS Changes

Actuant Corporation ATU numbers were lowered at UBS. Shares are now seen reaching $32. Estimates were also lowered on first-quarter miss. Buy rating.

Con-Way CNW numbers were lowered at Citigroup. Shares are now seen reaching $30. Estimates were also lowered on sharp incremental margin discount, Citi said. Neutral rating.

3M MMM numbers were raised at Jefferies. Shares are now seen reaching $110. Estimates were also raised on adjustment for Ceradyne, Jefferies said. Buy rating.

Norfolk Southern NSC numbers lowered at Jefferies. Shares are now seen reaching $70. Estimates were also lowered on volatility, Jefferies said. Hold rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

View Comments (0)